Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
NCT ID: NCT05177744
Last Updated: 2025-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1156 participants
OBSERVATIONAL
2022-10-05
2025-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of Personalized Balanced Nutrition Concept Through an IT Platform
NCT05462444
Polish Mother and Child Cohort Study (REPRO_PL) - Follow up of the Children.
NCT01861548
Clinical and Immunological Evaluation of Children With Allergies
NCT00102570
Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites
NCT01052610
Management of Drug Hypersensitivity in Children
NCT02031120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will include visits:
1. Initial (screening) visit (V0 +3-6 months): written consent, assessment of inclusion and exclusion criteria, spirometry, Fractional exhaled nitric oxide (FeNO), questionnaires…
2. V2 (V0+6-9 months), questionnaires, environmental skin prick test (APT), sIgE (+ISAC), spirometry, FeNO, blood collection stool,
3. V2-V5 (V0+months 6-30 months)- regular visits (assessment) every 6 months, stool samples (second sampling)
4. Visit 4 (V0+18-24 months): environmental assessments, skin prick test (APT), sIgE (+ISAC), spirometry, FeNO, blood collection
5. V5 (last visit, V0+24-30 months)- final assessment of the study outcome measures, check and document consumption, adherence, preventive measures, level of control, therapy correction
Participants in the control group will be involved in collaboration with other outpatient clinics (eg. from surgical outpatient clinics who have had minor surgical procedures, from the Otorhinolaryngology- Ear, Nose, Throat (ENT) outpatient clinics at least 7 days after acute ear inflammation or laryngitis, from emergency ambulatory patients at least 7 days after acute respiratory illness, etc.). All participants who will be included in the control group should have a negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses. They will need to fulfil the ISAAC questionnaire for children perform spirometry and prick test with a standard palette of inhalational and nutritional allergens to exclude allergic diseases.
No intervention tests or methods will be involved in this study. Patients who will be involved in the study will continue to take their regular therapy (according to guidelines) i.e. conduct treatment and all other non-therapeutic measures as if they were not involved in the study. Any deterioration or emergency intervention will be specifically evaluated and recorded as additional visits.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
allergic (Zagreb, urban)
Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.
Subjects will be recruited from continental region in Croatia - Zagreb (urban)
No interventions assigned to this group
healthy subjects (Zagreb, urban)
Healthy subjects that will be recruited from continental region in Croatia - Zagreb (urban).
Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses.
No interventions assigned to this group
allergic (Slavonia, urban and rural)
Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.
Subjects will be recruited from continental region in Croatia - Slavonia (urban and rural)
No interventions assigned to this group
healthy subjects (Slavonia, urban and rural)
Healthy subjects that will be recruited from continental region in Croatia -(Slavonia, urban and rural).
Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses.
No interventions assigned to this group
allergic Mediterranean region (urban and rural population)
Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.
Subjects will be recruited from mediterranean region in Croatia - urban and rural
No interventions assigned to this group
healthy subjects Mediterranean region (urban and rural population)
Healthy subjects that will be recruited from mediterranean region in Croatia -urban and rural.
Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of allergic rhinitis (AR) for at least 1 year with symptoms of the nose, induced after exposure to allergens via IgE-mediated hypersensitivity reactions (symptoms of watery rhinorrhea, nasal obstruction, nasal itching and sneezing).
* Diagnosis of atopic dermatitis (AD) with AD symptoms lasting for more than 3 months, with or without food allergy
• Significant clinical allergy to indoor and outdoor allergens, an food allergens with positive skin prick test (SPT) and specific IgE levels (\>0.35kUA/L)
Exclusion Criteria
* Pulmonary malformation
* Oxygen therapy after birth with a duration of more than 24 h
* Ventilator support or mechanical ventilation after birth
* Diagnosis of cystic fibrosis
* Primary ciliary dyskinesia
* Heart failure diagnosed after birth affecting pulmonary circulation
* Major respiratory diseases such as e.g. interstitial lung disease and other congenital and serious chronic disease
* Fever of at least 38.5 °C during the last two weeks prior to the planned visit
6 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Belgrade
OTHER
Children's Hospital Srebrnjak
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mirjana Turkalj, MD
Professor, MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital Srebrnjak
Zagreb, City of Zagreb, Croatia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCH-EU965173
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.